Price$46.73-0.14 (-0.29%)
01:30 PM07:45 PM
News · 26 weeks55+33%
2026-03-012026-08-23
Mix2090d
- SEC Filings17(85%)
- Other2(10%)
- Analyst1(5%)
Latest news
25 items- PRA New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.Issued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time and gravity take away: fill a wrinkle, restore lost volume, reshape a contour. Now a shift in the underlying science is pointing toward something more ambitious. Instead of simply replacing volume, a growing body of research is asking whether the body's own tissue can be prompted to rebuild itself, and a new commercial category is beginning to form around that idea. At the center of the science is a structure most people have never heard of, the extracellular matrix, the frame
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- ANALYSTNovo Nordisk A/S downgraded by BerenbergBerenberg downgraded Novo Nordisk A/S from Buy to Hold
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- PROne Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical AestheticsIssued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative platform toward a predicate-based 510(k).USA News Group News CommentaryRENO, Nev. , July 9, 2026 /CNW/ -- In regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one problem. That is the framing behind a milestone from Conexeu Sciences Inc. (NASDAQ:CNXU), a preclinical-stage regenerative tissue company that has completed the P
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form SD filed by Novo Nordisk A/SSD - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- PRPeptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness MarketsNEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness, recovery, longevity, weight management, and overall wellness. Peptides are being widely explored for areas tied to muscle recovery, metabolic health, anti-aging research, and performance optimization. What used to be a niche biotech category is now attracting attention from wellness brands, pharmaceutical companies, and investors looking for exposure to one of the faster-growing areas of healthcare innovation. Those seeking high-growth opportunities in wellness and biotech should watch these c
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
NVO FAQ
7 questionsWhat does Novo Nordisk A/S do?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop...Where does NVO stock trade?
Novo Nordisk A/S (NVO) is listed on NYSE.What sector and industry is NVO in?
Novo Nordisk A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does NVO pay a dividend?
NVO's most recent ex-dividend date was 2026-08-17 with a cash dividend of $0.41 per share. No future ex-date is on file yet.What are analysts saying about NVO?
Novo Nordisk A/S has had 8 recent analyst actions on file. The most recent action was from Berenberg: Hold on 2026-08-12. Recent price targets range from $4000.00 to $4200.00.What companies are similar to NVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NVO side-by-side with any of them on Quantisnow.How can I track NVO on Quantisnow?
Quantisnow aggregates Novo Nordisk A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVO to receive live email and push alerts on every new disclosure.